SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-20-009389
Filing Date
2020-05-08
Accepted
2020-05-08 20:01:59
Documents
2
Period of Report
2020-04-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 5917
2 EXPLANATION OF RESPONSES s050820a.htm EX-99.1 4922
  Complete submission text file 0001567619-20-009389.txt   12517
Mailing Address 10628 SCIENCE CENTER DRIVE SUITE 225 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE SUITE 225 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Issuer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SARISSA CAPITAL MANAGEMENT LP 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830
Business Address C/O SARISSA CAPITAL MANAGEMENT LP 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 203 302 2330
Sarissa Capital Master Fund II LP (Reporting) CIK: 0001811636 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35670 | Film No.: 20862291